Propylallyltryptamine

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.^[1] It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).^[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT_1B, 5-HT_2A, 5-HT_2B, and 5-HT₆ receptors, but not of the serotonin 5-HT_1A receptor.^[1] It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).^[1] The chemical synthesis of PALT has been described.^[1] A notable analogue of PALT is iPALT (ASR-3003).^[1] PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.^[1]

Propylallyltryptamine

Clinical data
Other names	PALT; N-Propyl-N-allyltryptamine; ASR-3004; ASR3004
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code	None
Identifiers
IUPAC name N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-1-amine
CAS Number	2686297-71-0
PubChem CID	138903953
ChemSpider	102827331
Chemical and physical data
Formula	C16H22N2
Molar mass	242.366 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCN(CCC1=CNC2=CC=CC=C21)CC=C
InChI InChI=1S/C16H22N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h3,5-8,13,17H,1,4,9-12H2,2H3 Key:BPHDZENPKNMIRD-UHFFFAOYSA-N

See also

• Substituted tryptamine